Abstract
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.
MeSH terms
-
Anti-Inflammatory Agents / therapeutic use
-
Anticoagulants / therapeutic use
-
Antioxidants / therapeutic use
-
Clinical Trials as Topic
-
Combined Modality Therapy / methods*
-
Combined Modality Therapy / trends
-
Disease Progression
-
Endothelin Receptor Antagonists
-
Humans
-
Idiopathic Pulmonary Fibrosis* / physiopathology
-
Idiopathic Pulmonary Fibrosis* / therapy
-
Immunosuppressive Agents / therapeutic use
-
Lung Transplantation
-
Medication Therapy Management / trends*
-
Outcome Assessment, Health Care
-
Oxygen Inhalation Therapy / methods*
-
Palliative Care
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Anti-Inflammatory Agents
-
Anticoagulants
-
Antioxidants
-
Endothelin Receptor Antagonists
-
Immunosuppressive Agents
-
Tumor Necrosis Factor-alpha